Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical HCT with CD3/CD19 Depleted Grafts in Refractory Hematologic Malignancies
NCT00202917Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Feb 2004
- Primary completion
- Jul 2009
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD3/CD19 depleted hematopoietic stem cells in hematologic malignancy, sponsored by University Hospital Tübingen. Primary endpoints: Engraftment, Toxicity and 1 more. Started Feb 2004; status: completed.
02
Drugs
CD3/CD19 depleted hematopoietic stem cells
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT00202917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00202917.